ATE439346T1 - Verbindungen mit wachstumshormon freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon freisetzenden eigenschaften

Info

Publication number
ATE439346T1
ATE439346T1 AT99919125T AT99919125T ATE439346T1 AT E439346 T1 ATE439346 T1 AT E439346T1 AT 99919125 T AT99919125 T AT 99919125T AT 99919125 T AT99919125 T AT 99919125T AT E439346 T1 ATE439346 T1 AT E439346T1
Authority
AT
Austria
Prior art keywords
compounds
growth hormone
hormone releasing
releasing properties
disubstituted
Prior art date
Application number
AT99919125T
Other languages
English (en)
Inventor
Thomas Hansen
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE439346T1 publication Critical patent/ATE439346T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
AT99919125T 1998-05-11 1999-05-10 Verbindungen mit wachstumshormon freisetzenden eigenschaften ATE439346T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK63698 1998-05-11
DKPA199800875 1998-07-01
PCT/DK1999/000260 WO1999058501A1 (en) 1998-05-11 1999-05-10 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
ATE439346T1 true ATE439346T1 (de) 2009-08-15

Family

ID=26064372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99919125T ATE439346T1 (de) 1998-05-11 1999-05-10 Verbindungen mit wachstumshormon freisetzenden eigenschaften

Country Status (23)

Country Link
EP (1) EP1077941B1 (de)
JP (2) JP4142253B2 (de)
KR (1) KR100593601B1 (de)
CN (1) CN1142911C (de)
AT (1) ATE439346T1 (de)
AU (1) AU757217B2 (de)
BR (1) BR9910329A (de)
CA (1) CA2329881C (de)
CY (1) CY1109626T1 (de)
CZ (1) CZ301276B6 (de)
DE (1) DE69941255D1 (de)
DK (1) DK1077941T3 (de)
ES (1) ES2331102T3 (de)
HU (1) HUP0102071A3 (de)
IL (2) IL139090A0 (de)
NO (1) NO318080B1 (de)
PL (1) PL194560B1 (de)
PT (1) PT1077941E (de)
RU (1) RU2243215C2 (de)
SI (1) SI1077941T1 (de)
TW (1) TWI222969B (de)
UA (1) UA72210C2 (de)
WO (1) WO1999058501A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011872A3 (cs) 1999-09-29 2002-03-13 Ortho-Mcneil Pharmaceutical, Inc. Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2002046156A2 (en) 2000-12-06 2002-06-13 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
CA2438272A1 (en) * 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
DE10113604A1 (de) * 2001-03-20 2002-10-24 Ibfb Gmbh Privates Inst Fuer B Verfahren zur Spaltung des humanen Wachstumshormons GH
EP1389205B1 (de) 2001-04-09 2005-12-21 Ortho-McNeil Pharmaceutical Research Inc. Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
FR2827518B1 (fr) * 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
EP1407779A1 (de) 2002-10-10 2004-04-14 Gastrotech A/S Verwendung von Ghrelin zur Behandlung von vermindertem Körpergewicht und Körperfett in Individuen mit Gastrektomie
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
KR20070010151A (ko) * 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 c-반응성 단백질을감소시키는 방법
US7825138B2 (en) * 2004-06-29 2010-11-02 Helsinn Therapeutics (U.S.), Inc. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
BRPI0713119A2 (pt) * 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
WO2012131090A1 (en) 2011-03-31 2012-10-04 Galderma Research & Development Method for treatment of xeroderma pigmentosum
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960705808A (ko) * 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
FI974368A7 (fi) * 1995-05-29 1997-11-28 Pfizer Kasvuhormonin vapautumista edistäviä dipeptidejä
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
WO1997036873A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5922770A (en) * 1996-07-22 1999-07-13 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998010653A1 (en) * 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998016527A1 (en) * 1996-10-15 1998-04-23 Fujisawa Pharmaceutical Co., Ltd. Benzoxepine derivatives which promote release of growth hormone

Also Published As

Publication number Publication date
JP4142253B2 (ja) 2008-09-03
DE69941255D1 (de) 2009-09-24
JP4938708B2 (ja) 2012-05-23
IL139090A (en) 2007-03-08
CN1300281A (zh) 2001-06-20
NO20005668D0 (no) 2000-11-10
PL194560B1 (pl) 2007-06-29
CZ301276B6 (cs) 2009-12-30
PL344042A1 (en) 2001-09-24
CA2329881A1 (en) 1999-11-18
IL139090A0 (en) 2001-11-25
RU2243215C2 (ru) 2004-12-27
KR100593601B1 (ko) 2006-06-28
EP1077941A1 (de) 2001-02-28
CY1109626T1 (el) 2014-08-13
HUP0102071A2 (hu) 2002-03-28
CA2329881C (en) 2010-03-16
JP2004500312A (ja) 2004-01-08
BR9910329A (pt) 2001-01-30
EP1077941B1 (de) 2009-08-12
NO318080B1 (no) 2005-01-31
PT1077941E (pt) 2010-07-01
JP2008156372A (ja) 2008-07-10
TWI222969B (en) 2004-11-01
CZ20004129A3 (en) 2001-06-13
CN1142911C (zh) 2004-03-24
ES2331102T3 (es) 2009-12-21
SI1077941T1 (sl) 2010-01-29
AU3701099A (en) 1999-11-29
WO1999058501A1 (en) 1999-11-18
UA72210C2 (uk) 2005-02-15
HUP0102071A3 (en) 2002-06-28
DK1077941T3 (da) 2009-12-07
NO20005668L (no) 2001-01-10
AU757217B2 (en) 2003-02-06
KR20010043422A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
ATE439346T1 (de) Verbindungen mit wachstumshormon freisetzenden eigenschaften
BG105256A (en) Muscarinic agonists and antagonists
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
BG104916A (en) Calcilytic compounds
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
CY1111509T1 (el) Ενωσεις με ιδιοτητες απελευθερωσης αυξητικης ορμονης
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
SE9802937D0 (sv) Novel compounds
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE59900546D1 (de) Pseudoböhmit und gamma al2o3 enthaltender trägerkatalysator, dessen herstellung und dessen verwendung zur herstellung von 1,2-dichlorethan
YU58600A (sh) Oblik vi 5,6-dihloro-2-(izopropilamino)-1-(beta-l-ribofuranozil)-1h-benzimidazola
DE69426021D1 (de) Xamonelin-Tartrat
IL139531A0 (en) Human antithrombin iii, methods for the production thereof and pharmaceutical compositions containing the same
ATE281467T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69919195D1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
DE68900131D1 (de) Biozide 4,5-dichlor-1,2-dithiol-3-on-zusammensetzung.
ES8505363A1 (es) Un procedimiento para preparar una 3-(2-furoil)-5-2,6-dimetil-4-(2-nitrofenil)-1,4-dihidropiridina
MY102063A (en) New use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
UA67058A (en) Composition for treating periodontitis
PE61999A1 (es) Compuestos de tetrahidropiridina
ITRM930135V0 (it) Piombo per pesca, in particolare pesca del tipo "surf-casting".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1077941

Country of ref document: EP